When the body treats a therapeutic antibody as foreign, it produces anti-drug antibodies that can blunt the drug’s effect, change how it moves through the body and raise safety concerns. The FDA’s ...

Patients with gMG who lack detectable anti-AChR antibodies — a group historically excluded from clinical trials — show sustained benefits with efgartigimod.

"Dupixent," a massive mega-blockbuster with annual sales exceeding $13 billion. The golden duo of Sanofi and Regeneron, who ...

Exploratory phase 3 data suggest that gefurulimab may reduce the need for rescue therapy and hospitalizations in patients ...

Immunovant's IMVT-1402 aims to deliver best-in-class FcRn inhibition, but mixed data tempers confidence in its superiority.

Eptinezumab treatment reduces monthly migraine days and acute medication use in patients with difficult-to-treat episodic or chronic migraine.

Miv-cel reversed disability and achieved durable efficacy across all primary and secondary endpoints through one year, with nearly all patients ...

ORKA-001 ultra-long-acting psoriasis data (PASI 100/90), cash runway, and catalysts. Click for more on ORKA stock.

Breast cancer during pregnancy can often be treated safely. Lynn Cancer Institute and Lynn Women’s Institute experts explain ...

Researchers have built a core-shell Ag@Au nanoparticle biosensor that pairs plasmonic sensing with smartphone-based machine ...

Summit Therapeutics Inc. (NASDAQ: SMMT) today announced a clinical trial collaboration with the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) to evaluate ivonescimab, a novel, potential first-in-class ...